id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2004-D-0182-0005,FDA,FDA-2004-D-0182,FDA,Notice,NAD-Notice of Availability of Data,2007-07-09T04:00:00Z,2007,7,2007-07-06T04:00:00Z,2008-07-08T03:59:59Z,2008-04-12T00:34:48Z,,0,0,0900006480470230
FDA-2004-D-0182-0004,FDA,FDA-2004-D-0182,"Guidance for Industry; ANDAs: Pharmaceutical Solid Polymorphism;
Chemistry, Manufacturing, and Controls Information",Other,Guidance,2007-07-06T04:00:00Z,2007,7,2007-07-06T04:00:00Z,,2024-11-12T04:12:14Z,,1,0,090000648047022f
FDA-2004-D-0182-0003,FDA,FDA-2004-D-0182,Guidance,Supporting & Related Material,GDL-Guidance,2004-12-27T05:00:00Z,2004,12,,,2008-04-12T00:34:48Z,,0,0,0900006480470216
FDA-2004-D-0182-0001,FDA,FDA-2004-D-0182,FDA,Notice,NAD-Notice of Availability of Data,2004-12-27T05:00:00Z,2004,12,2004-12-20T05:00:00Z,2005-03-22T04:59:59Z,2008-04-12T00:34:48Z,,0,0,0900006480470214
FDA-2004-D-0182-0002,FDA,FDA-2004-D-0182,Guidance,Supporting & Related Material,GDL-Guidance,2004-12-27T05:00:00Z,2004,12,,,2008-04-12T00:34:48Z,,0,0,0900006480470215